Payment overview · 2025
General Payments
$382.14
22 reported records · 8 companies
Healthcare provider profile · identity verified
Stephanie Jane Russ, DO
Allopathic & Osteopathic Physicians|Family Medicine · PENDLETON, IN · NPI 1629239355
Verified facts
What the public records show
CMS Open Payments records show Stephanie Jane Russ, DO received $382.14 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.77 | 24.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.36 | 18.7% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.45 | 18.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.64 | 13.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.91 | 12.5% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.54 | 5.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.46 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.01 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.14 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.36 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.45 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 47 |
| Lisinopril | Lisinopril | 175 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 45 |
| Losartan Potassium | Losartan Potassium | 151 | 43 |
| Metformin Hcl Er | Metformin Hcl | 102 | 30 |
| Omeprazole | Omeprazole | 98 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 22 |
| Simvastatin | Simvastatin | 87 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 20 |
| Metformin Hcl | Metformin Hcl | 58 | 21 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 18 |
| Montelukast Sodium | Montelukast Sodium | 56 | 19 |
| Atenolol | Atenolol | 54 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Meloxicam | Meloxicam | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 15 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Famotidine | Famotidine | 39 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Gabapentin | Gabapentin | 35 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 13 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 12 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Prednisone | Prednisone | 20 | 15 |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.14 · 22 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, FARXIGA, Jornay PM, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SAPIEN 3 Ultra RESILIA, VOQUEZNA, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error